Drugs / Ricolinostat
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05193851 | Jan 2022 | peripheral nervous system disorder | Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02856568 | May 2017 → Oct 2021 | hilar cholangiocarcinoma | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 1 | NCT02661815 | Jun 2016 → Jun 2017 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT02787369 | May 2016 → Apr 2026 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02189343 | Sep 2014 → Apr 2018 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02088398 | Mar → Apr 2014 | — | Acetylon Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT01583283 | Jul 2012 → Mar 2021 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02091063 | Apr 2014 → Feb 2019 | lymphoma | Jennifer Amengual | Terminated | No outcome recorded |
| Phase 1/2 | NCT01997840 | Mar 2014 → Feb 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT01323751 | Jul 2011 → Dec 2016 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03176472 | Dec 2020 → Oct 2022 | diabetic polyneuropathy | Regenacy Pharmaceuticals LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05229042 Comparator | Jan 2022 → Nov 2023 | peripheral nervous system disorder | Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02632071 Comparator | Mar 2016 → Sep 2020 | breast carcinoma | Columbia University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ricolinostat | “Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically.” PMID 27646843 ↗ Sep 20167“Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects” NCT02088398 ↗ “ACY-1215 (Ricolinostat)” NCT02189343 ↗ |
| Known as | ACY-1215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02632071 ↗ |
| Known as | ACY-1215 (Ricolinostat) | “ACY-1215 (Ricolinostat)” NCT02189343 ↗ |
| Known as | ACY-63 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364628 ↗ |
| Action | Inhibit | “HDAC6 inhibitor” NCT01323751 ↗ |
| Modality | Small molecule | “small-molecule enzyme inhibitor” NCT02091063 ↗ |
| Route | Oral | “Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle” NCT01323751 ↗ |
| Target | HDAC6 | “HDAC6 inhibitor” NCT01323751 ↗ |